- Home
- HNNA vs TCRX Comparison
HNNA vs TCRX Comparison
Compare HNNA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNNA
- TCRX
- Stock Information
- Founded
- HNNA 1989
- TCRX 2018
- Country
- HNNA United States
- TCRX United States
- Employees
- HNNA N/A
- TCRX N/A
- Industry
- HNNA Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- HNNA Finance
- TCRX Health Care
- Exchange
- HNNA Nasdaq
- TCRX Nasdaq
- Market Cap
- HNNA 98.7M
- TCRX 82.1M
- IPO Year
- HNNA N/A
- TCRX 2021
- Fundamental
- Price
- HNNA $12.55
- TCRX $1.82
- Analyst Decision
- HNNA
- TCRX Strong Buy
- Analyst Count
- HNNA 0
- TCRX 6
- Target Price
- HNNA N/A
- TCRX $9.50
- AVG Volume (30 Days)
- HNNA 6.7K
- TCRX 619.4K
- Earning Date
- HNNA 08-07-2025
- TCRX 08-11-2025
- Dividend Yield
- HNNA 4.32%
- TCRX N/A
- EPS Growth
- HNNA 83.55
- TCRX N/A
- EPS
- HNNA 1.25
- TCRX N/A
- Revenue
- HNNA $35,546,000.00
- TCRX $4,421,000.00
- Revenue This Year
- HNNA N/A
- TCRX $159.20
- Revenue Next Year
- HNNA N/A
- TCRX N/A
- P/E Ratio
- HNNA $10.17
- TCRX N/A
- Revenue Growth
- HNNA 41.94
- TCRX N/A
- 52 Week Low
- HNNA $7.65
- TCRX $1.02
- 52 Week High
- HNNA $13.88
- TCRX $7.64
- Technical
- Relative Strength Index (RSI)
- HNNA 64.54
- TCRX 57.99
- Support Level
- HNNA $11.60
- TCRX $1.75
- Resistance Level
- HNNA $12.42
- TCRX $1.94
- Average True Range (ATR)
- HNNA 0.42
- TCRX 0.13
- MACD
- HNNA -0.05
- TCRX 0.02
- Stochastic Oscillator
- HNNA 75.17
- TCRX 77.78
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.